This is in concordance with previous studies hinting at a reduced PFS and OS for SUFU mutated patients compared to PTCH1 mutated patients or SHH activated DMB/MBEN medulloblastoma patients in general (45, 57). This evidence concerns the gene HLA-DMB and medulloblastoma.